These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 31094010)

  • 1. Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
    Park JW; Kim KA; Choi YJ; Yoon SH; Park JY
    J Clin Pharm Ther; 2019 Oct; 44(5):720-725. PubMed ID: 31094010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.
    Nakamaru Y; Hayashi Y; Davies M; Jürgen Heuer H; Hisanaga N; Akimoto K
    Clin Ther; 2015 Sep; 37(9):2007-18. PubMed ID: 26212570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
    Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
    Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
    Kinoshita S; Kondo K
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):7-14. PubMed ID: 25424014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
    Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
    Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
    Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
    J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
    Choi HY; Kim YH; Kim MJ; Lee SH; Bang K; Han S; Lim HS; Bae KS
    Drugs R D; 2014 Sep; 14(3):165-76. PubMed ID: 24962635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
    Yoo H; Kim Y; Jang IJ; Yu KS; Lee S
    Drug Des Devel Ther; 2020; 14():5179-5187. PubMed ID: 33262578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
    Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
    Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the
    Kim CO; Oh ES; Kim H; Park MS
    Drug Des Devel Ther; 2017; 11():503-512. PubMed ID: 28260863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teneligliptin for the treatment of type 2 diabetes.
    Goda M; Kadowaki T
    Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
    Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
    Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
    Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
    Smulders RA; Zhang W; Veltkamp SA; van Dijk J; Krauwinkel WJ; Keirns J; Kadokura T
    Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population.
    Cho HJ; Lee SY; Kim YG; Oh SY; Kim JW; Huh W; Ko JW; Kim HG
    Clin Chim Acta; 2011 Sep; 412(19-20):1831-4. PubMed ID: 21704609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of
    Park JW; Kim KA; Kim JM; Park IH; Park JY
    Front Pharmacol; 2021; 12():736317. PubMed ID: 34512362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.